Edition:
United Kingdom

People: Editas Medicine Inc (EDIT.OQ)

EDIT.OQ on NASDAQ Stock Exchange Global Select Market

27.01USD
24 Apr 2019
Change (% chg)

$-0.43 (-1.57%)
Prev Close
$27.44
Open
$27.52
Day's High
$27.60
Day's Low
$26.49
Volume
207,194
Avg. Vol
324,042
52-wk High
$41.40
52-wk Low
$17.90

Bosley, Katrine 

Ms. Katrine S. Bosley is President, Director of the company. she was , Chief Executive Officer of the company. She has served as our President and Chief Executive Officer and a member of our board of directors since June 2014. Prior to joining Editas, Ms. Bosley was the Entrepreneur-in-Residence at The Broad Institute from September 2013 to May 2014. She served as Chief Executive Officer of Avila Therapeutics Inc., or Avila, a biotechnology company, from May 2009 to March 2012, when Avila was acquired by Celgene Corporation, or Celgene, a public biopharmaceutical company. Ms. Bosley served as President, Celgene Avilomics Research at Celgene from March 2012 to May 2012. Before Avila, she was Vice President, Strategic Operations at Adnexus, a Bristol-Myers Squibb Company and was Vice President, Business Development at Adnexus Therapeutics Inc., or Adnexus, a biotechnology company, before that. She joined Adnexus from Biogen Idec, Inc., a public biotechnology company, where she held roles in business development, commercial operations, and portfolio strategy in the United States and Europe. Earlier, she was part of the healthcare team at the venture firm Highland Capital Partners. Ms. Bosley currently serves as chairman of the board of directors of Genocea Biosciences, Inc., a public biotechnology company, and is a director of Galapagos NV, a public biotechnology company. She also serves on the board of directors of the Biotechnology Industry Organization, a not-for-profit organization. Ms. Bosley graduated from Cornell University with a B.A. in biological sciences. We believe that Ms. Bosley’s operational and historical experience with Editas gained from serving as our President and Chief Executive Officer and member of our board of directors, combined with her prior experiences in creating strategic and business development value and her network in the biopharmaceutical industry, qualifies her to serve as a member of our board of directors.

Basic Compensation

Total Annual Compensation, USD 777,400
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 5,314,100
Fiscal Year Total, USD 6,091,500

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

James Mullen

--

Katrine Bosley

6,091,500

Cynthia Collins

--

Charles Albright

1,266,640

Gerald Cox

2,467,450

Andrew Hirsch

246,416
As Of  31 Dec 2017